—Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker—

—Additional Analyses Will Highlight Efficacy, Symptom Reduction, and Biomarker Suppression in Patients with Non-Cystic Fibrosis Bronchiectasis—

BRIDGEWATER, N.J., Oct. 16, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present six abstracts from the Phase 3 ASPEN study of BRINSUPRI™ (brensocatib) at CHEST 2025, the American College of Chest Physicians Annual Meeting, taking place October 19 - October 22, 2025, in Chicago, IL.

Presentations will feature new prespecified and post-hoc subgrou

See Full Page